Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: microRNA therapeutics - Regulus Therapeutics

Drug Profile

Research programme: microRNA therapeutics - Regulus Therapeutics

Alternative Names: anti-miR-10b; anti-miR-122; anti-miR-132; miR-122; miR-296; miR-34; miR-34a; miR-K12-11 (viral oncomir); miR-X; miRNA therapeutics - Regulus Therapeutics; RGLS 5579; RGLS 6650; Viral microRNAs - Regulus Therapeutics

Latest Information Update: 28 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator California Institute of Technology/CalTech; Stanford University
  • Developer Brigham and Women's Hospital; Cenix BioScience; Regulus Therapeutics
  • Class Anti-infectives; Antihyperglycaemics; Antineoplastics; Antisense oligonucleotides; Antivirals; Cardiovascular therapies; Heart failure therapies; Hepatoprotectants; MicroRNAs
  • Mechanism of Action MicroRNA inhibitors; MicroRNA modulators; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Non-alcoholic steatohepatitis

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis
  • No development reported Glioblastoma; Hepatitis B; Hepatitis C; Immunological disorders; Infections; Non-alcoholic steatohepatitis
  • Discontinued Diabetes mellitus; Heart failure; Metabolic syndrome; Viral infections

Most Recent Events

  • 28 Jun 2023 No recent reports of development identified for preclinical development in Hepatitis-C in USA
  • 28 Feb 2023 No recent reports of development identified for preclinical development in Immunological-disorders in USA
  • 28 Feb 2023 No recent reports of development identified for preclinical development in Infections in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top